Asthma ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes asthma ‐ childhood (incidence) compared with cow's milk formula ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Eczema ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes eczema ‐ childhood (incidence) compared with cow's milk formula ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Relapse · Participants with Crohn's disease in remission
It is very uncertain whether elemental formula supplements changes relapse compared with polymeric formula supplements (very low certainty).
1 finding from 1 review
Change in weight (kg) · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in height · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Participants with Crohn's disease in remission
Elemental formula supplements showed no clear difference in withdrawals due to adverse events compared with polymeric formula supplements (low certainty).
1 finding from 1 review
Chlorhexidine oral product (one formulation/concentration) vs Another chlorhexidine formulation, concentration or application frequency
Outcome not reported · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
All allergic disease ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes all allergic disease ‐ childhood (incidence) compared with human milk feeding ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Asthma ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes asthma ‐ childhood (incidence) compared with human milk feeding ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Eczema ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes eczema ‐ childhood (incidence) compared with human milk feeding ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Food allergy ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes food allergy ‐ childhood (incidence) compared with human milk feeding ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Cow's milk allergy ‐ infancy (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes cow's milk allergy ‐ infancy (incidence) compared with human milk feeding ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Cow's milk allergy ‐ childhood (incidence) · infants not selected for allergic disease risk.
It is very uncertain whether early short‐term feeding: hydrolysed formula changes cow's milk allergy ‐ childhood (incidence) compared with human milk feeding ‐ low‐risk infants (very low certainty).
1 finding from 1 review
Virologic failure 2 successive HIV‐1 RNA >= 200copies/ml at 16+ weeks after randomisation · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in virologic failure 2 successive HIV‐1 RNA >= 200copies/ml at 16+… compared with NNRTIs or PIs (moderate certainty).
1 finding from 1 review
Virologic suppression Viral load < 50 copies/ml · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in virologic suppression Viral load < 50 copies/ml compared with NNRTIs or PIs (moderate certainty).
1 finding from 1 review
CD4 cell count · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
1 finding from 1 review
Severe adverse events · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in severe adverse events compared with NNRTIs or PIs (moderate certainty).
1 finding from 1 review